AbbVie Inc. [NYSE: ABBV] loss -0.59% on the last trading session, reaching $108.50 price per share at the time. The company report on October 15, 2021 that AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU).
– CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2,.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
– If approved, this will mark the second indication for risankizumab in the EU.
AbbVie Inc. represents 1.77 billion in outstanding shares, while the company has a total market value of $191.07 billion with the latest information. ABBV stock price has been found in the range of $107.75 to $109.14.
If compared to the average trading volume of 7.10M shares, ABBV reached a trading volume of 5672825 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AbbVie Inc. [ABBV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $127.01 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 27, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Outperform. The new note on the price target was released on April 07, 2021, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $120, while Bernstein analysts kept a Outperform rating on ABBV stock.
The Average True Range (ATR) for AbbVie Inc. is set at 1.63, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 3.56. The Price to Book ratio for the last quarter was 15.26, with the Price to Cash per share for the same quarter was set at 4.88. Price to Free Cash Flow for ABBV in the course of the last twelve months was 17.79 with Quick ratio for the last quarter at 0.80.
Trading performance analysis for ABBV stock
AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.00. With this latest performance, ABBV shares gained by 1.34% in over the last four-week period, additionally sinking by -2.64% over the last 6 months – not to mention a rise of 28.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 46.45, with the RSI for the last a single of trading hit 47.35, and the three-weeks RSI is set at 45.64 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 111.20, while it was recorded at 108.45 for the last single week of trading, and 111.28 for the last 200 days.
AbbVie Inc. [ABBV]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +34.12 and a Gross Margin at +69.18. AbbVie Inc.’s Net Margin is presently recorded at +9.95.
Return on Total Capital for ABBV is now 19.65, given the latest momentum, and Return on Invested Capital for the company is 6.22. Return on Equity for this stock inclined to 185.81, with Return on Assets sitting at 3.80. When it comes to the capital structure of this company, AbbVie Inc. [ABBV] has a Total Debt to Total Equity ratio set at 665.82. Additionally, ABBV Total Debt to Total Capital is recorded at 86.94, with Total Debt to Total Assets ending up at 57.82. Long-Term Debt to Equity for the company is recorded at 599.46, with the Long-Term Debt to Total Capital now at 78.28.
Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $96,936 per employee. Receivables Turnover for the company is 6.43 with a Total Asset Turnover recorded at a value of 0.38.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.90.
AbbVie Inc. [ABBV]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 4.62%.
An analysis of insider ownership at AbbVie Inc. [ABBV]
There are presently around $129,482 million, or 68.90% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 144,693,566, which is approximately 0.668% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 122,591,994 shares of the stock with an approximate value of $13.3 billion in ABBV stocks shares; and STATE STREET CORP, currently with $8.24 billion in ABBV stock with ownership of nearly 0.619% of the company’s market capitalization.
Positions in AbbVie Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,427 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 53,737,340 shares. Additionally, 962 investors decreased positions by around 47,371,180 shares, while 335 investors held positions by with 1,092,275,564 shares. The mentioned changes placed institutional holdings at 1,193,384,084 shares, according to the latest SEC report filing. ABBV stock had 138 new institutional investments in for a total of 9,091,290 shares, while 73 institutional investors sold positions of 3,290,064 shares during the same period.